David Cabral, MD
Internal Medicine · Hickory, NCNPI 1407031420
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 176 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 32 manufacturers reported payments, led by Kowa Pharmaceuticals America, Inc. at 27.7% of the total. Reporting peaked in 2020 at $651 and has fallen 53.2% since, to $305 in 2025.
Across 176 payments — averaging $15.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Kowa Pharmaceuticals America, Inc.$738
- Novo Nordisk$240
- AstraZeneca$205
- Abbott$152
- Amarin Pharma, Inc.$140
- Sanofi-aventis U.S. LLC$127
- plus $1K from 26 others
What the payments were for
- Food & beverage$2,669100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Kowa Pharmaceuticals America, Inc. | 62 | $738 |
| Novo Nordisk | 16 | $240 |
| AstraZeneca | 13 | $205 |
| Abbott | 7 | $152 |
| Amarin Pharma, Inc. | 9 | $140 |
| Sanofi-aventis U.S. LLC | 6 | $127 |
| Exact Sciences | 8 | $118 |
| Bayer | 5 | $101 |
| Amgen | 5 | $88 |
| Johnson & Johnson | 6 | $82 |
| AbbVie | 4 | $80 |
| Pfizer | 5 | $80 |
| Xeris Pharmaceuticals, Inc. | 1 | $52 |
| Avanir Pharmaceuticals, Inc. | 3 | $50 |
| Almatica Pharma LLC | 3 | $45 |
| Merck | 3 | $42 |
| Lilly USA, LLC | 2 | $33 |
| Shield Therapeutics Inc | 2 | $29 |
| Novartis | 2 | $28 |
| Sanofi Pasteur Inc. | 1 | $26 |
| Teva Pharmaceuticals USA, Inc. | 2 | $24 |
| Seqirus USA Inc | 1 | $22 |
| Alvogen Inc | 1 | $21 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $20 |
| GSK | 1 | $19 |
| Boehringer Ingelheim | 1 | $19 |
| Phathom Pharmaceuticals, Inc. | 1 | $17 |
| Astellas Pharma US Inc | 1 | $17 |
| Boston Scientific | 1 | $15 |
| Zyla Life Sciences, Inc. | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
| Nevro Corp. | 1 | $12 |
How this compares
$2,669 in reported general payments places this provider in the 85th percentile of 3,302 internal medicine providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 178 | $205,374 |
| EliquisApixaban | 141 | $121,185 |
| LinzessLinaclotide | 51 | $40,808 |
| JardianceEmpagliflozin | 24 | $30,164 |
| XareltoRivaroxaban | 33 | $26,491 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 29 | $25,457 |
| JanuviaSitagliptin Phosphate | 27 | $25,416 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 28 | $18,236 |
| SymbicortBudesonide/Formoterol Fumarate | 39 | $10,750 |
| Repatha SureclickEvolocumab | 16 | $10,054 |
| MyrbetriqMirabegron | 13 | $9,282 |
| BrilintaTicagrelor | 14 | $6,049 |
| Atorvastatin Calcium | 512 | $3,625 |
| SynthroidLevothyroxine Sodium | 42 | $3,535 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 18 | $3,259 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $240 | $205,374178 claims |
| PfizerEliquis | $80 | $121,185141 claims |
| AbbVieLinzess, Synthroid | $80 | $44,34393 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Brilinta | $205 | $42,25682 claims |
| Boehringer IngelheimJardiance | $19 | $30,16424 claims |
| Johnson & JohnsonXarelto | $82 | $26,49133 claims |
| MerckJanuvia | $42 | $25,41627 claims |
| GSKTrelegy Ellipta | $19 | $18,23628 claims |
| Astellas Pharma US IncMyrbetriq | $17 | $9,28213 claims |
| Lilly USA, LLCHumulin N | $33 | $1,43911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,302 internal medicine providers in North Carolina.
Other internal medicine in Hickory
- Nirmish ShahDurham$862K
- Eugene WrightFayetteville$839K
- Saad UsmaniCharlotte$551K
- Bhakti PaulRaleigh$536K
- Mary KlotmanDurham$478K
- Manesh PatelDurham$435K
- Millie LongChapel Hill$374K
- Marc JohnsonCharlotte$342K
- Christina CraterRaleigh$330K
- Jamy ArdWinston Salem$293K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.